Meridian Bioscience (NASDAQ: VIVO) reported Q4 EPS of $0.23, $0.03 better than the analyst estimate of $0.20. Revenue for the quarter came in at $76.2 million versus the consensus estimate of $68.4 million.

GUIDANCE:

Meridian Bioscience sees FY2022 EPS of $0.98-$1.08, versus the consensus of $1.63. Meridian Bioscience sees FY2022 revenue of $285-300 million, versus the consensus of $310 million.

For earnings history and earnings-related data on Meridian Bioscience (VIVO) click here.